These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32010561)

  • 1. Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis.
    Zhao Y; Wan B; Zhang T; Xu Y; Liu H; Lv T; Zhang F; Zhan P; Song Y
    Transl Lung Cancer Res; 2019 Dec; 8(6):829-837. PubMed ID: 32010561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as 
Second-line Treatment for Small Cell Lung Cancer].
    Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.
    Aktas G; Kus T; Kalender ME; Sevinc A; Camci C; Kul S
    Onco Targets Ther; 2016; 9():1921-6. PubMed ID: 27099522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Song Z; Shao L; Lin B; Zhang Y
    Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
    He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
    Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].
    Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):572-8. PubMed ID: 24229622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.
    Lambrecht L; Arnold P; Behr J; Mertsch P; Tufman A; Kauffmann-Guerrero D
    Diagnostics (Basel); 2024 Jul; 14(14):. PubMed ID: 39061709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.
    Ardizzoni A; Tiseo M; Boni L
    Eur J Cancer; 2014 Sep; 50(13):2211-8. PubMed ID: 24981975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy versus best supportive care for extensive small cell lung cancer.
    Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
    Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD001990. PubMed ID: 24282143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study.
    Du Y; Liu XY; Si XY; Zhang XT; Zhou JY; Wang Y; Chen MJ; Zhang L
    Transl Lung Cancer Res; 2024 Jul; 13(7):1518-1529. PubMed ID: 39118888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
    Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201.
    Yamamoto S; Kawakami H; Kii T; Hara H; Kawabata R; Kawada J; Takeno A; Matsuyama J; Ueda S; Okita Y; Endo S; Kimura Y; Yanagihara K; Okuno T; Kurokawa Y; Shimokawa T; Satoh T
    Eur J Cancer; 2021 Sep; 154():307-315. PubMed ID: 34311300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of prognostic factors in Chinese patients with small cell lung cancer: A retrospective study of 999 patients.
    Hong X; Xu Q; Yang Z; Wang M; Yang F; Gao Y; Zhou F; Wang L; Liu B; Chen G
    Clin Respir J; 2018 Feb; 12(2):433-447. PubMed ID: 27460525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
    Kim SH; Kim MJ; Kim YJ; Chang H; Kim JW; Lee JO; Lee KW; Kim JH; Bang SM; Lee JS
    Medicine (Baltimore); 2017 Oct; 96(42):e8176. PubMed ID: 29049199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
    Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
    Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.